Veradermics (MANE)

Executive Summary

Veradermics is a late clinical-stage biopharmaceutical company pioneering innovative therapies for common dermatologic and aesthetic conditions. Its lead candidate, VDPHL01, is an extended-release oral minoxidil designed as the first non-hormonal oral treatment for androgenetic alopecia (pattern hair loss) in both men and women, addressing a significant innovation gap of over 30 years. The company is currently conducting multiple Phase 2 and Phase 3 trials evaluating VDPHL01, with top-line data expected in the second half of 2026. Additionally, Veradermics has completed a Phase 2 study of VDMN-21, a topical patch for verruca vulgaris (common warts), and may advance this program. As a publicly traded company (NASDAQ: MANE) with a market valuation of ~$2.6 billion, Veradermics is positioned to capture a substantial share of the large, underserved hair loss market pending successful clinical outcomes and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Top-Line Data for VDPHL01 in AGA (NCT06527365)70% success
• Q3 2026Phase 2/3 Data Readout for VDPHL01 (NCT06724614)65% success
• TBDPotential Regulatory Submission or Guidance for VDPHL0140% success